Hepatocellular protection by nitric oxide or nitrite in ischemia and reperfusion injury by Abe, Yuta et al.
Hepatocellular Protection by Nitric Oxide or Nitrite in Ischemia and
Reperfusion Injury
Yuta Abe1, Ian Hines2, Gazi Zibari3, and Matthew B. Grisham1
1 Department of Molecular and Cellular Physiology, LSU Health Sciences Center, Shreveport, LA 71130
2 Department of Medicine, Division of Gastroenterology and Hepatology, MBRB 7336 Campus Box #7032,
University of North Carolina, Chapel Hill, NC 27599
3 Department of Surgery, LSU Health Sciences Center, Shreveport, LA 71130
Abstract
Ischemia and reperfusion (I/R)-induced liver injury occurs in several pathophysiological disorders
including hemorrhagic shock and burn as well as resectional and transplantation surgery. One of the
earliest events associated with reperfusion of ischemic liver is endothelial dysfunction characterized
by the decreased production of endothelial cell-derived nitric oxide (NO). This rapid post-ischemic
decrease in NO bioavailability appears to be due to decreased synthesis of NO, enhanced inactivation
of NO by the overproduction of superoxide or both. This review presents the most current evidence
supporting the concept that decreased bioavailability of NO concomitant with enhanced production
of reactive oxygen species initiates hepatocellular injury and that endogenous NO or exogenous NO
produced from nitrite play important roles in limiting post-ischemic tissue injury.
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Introduction
Hepatic ischemia followed by reperfusion results in tissue injury that contributes substantially
to the morbidity and mortality associated with shock, thermal injury, liver transplantation and
resectional surgery. Indeed, liver ischemia and reperfusion (I/R)-induced hepatocellular
damage is thought to be responsible for up to 10% of organ dysfunction in liver transplantation
leading to acute and chronic rejection. Experimental and clinical evidence suggest that post-
ischemic tissue damage occurs in an antigen-independent manner in which tissue injury
initiates a cascade of innate immune responses that ultimately results in liver failure. For the
warm I/R that occurs in shock or liver resectional surgery, it has been demonstrated that tissue
damage occurs in two distinct phases termed the early (acute) phase and the late (subacute)
phase [1–3]. The early phase of injury occurs in the absence of leukocyte infiltration and is
thought to be initiated by a rapid change in the redox state of the tissue in favor of a more
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oxidative environment. The late phase of injury is dependent upon the production of several
different cytokines and chemokines that promote the infiltration of large numbers of leukocytes
into the tissue [1–4]. Extravasated polymorphonuclear leukocytes (PMNs) become
metabolically activated and release large amounts of reactive oxygen species (ROS) together
with extracellular matrix degrading enzymes such as collagenase and matrix metalloproteases
[5]. The net result of this inflammatory infiltrate is an amplification of the acute injurious
responses resulting in extensive inflammatory tissue injury.
It is well-appreciated that endogenous nitric oxide (NO) may act to limit ROS- and PMN-
mediated tissue injury as well as attenuate the subsequent inflammatory response in vivo [6–
11]. Indeed, it has been demostrated that I/R-induced cellular injury is associated with a
remarkable decrease in the bio-availability of NO which represents an important initiating
event in the pathophysiology of post-ischemic injury in a variety of different tissues including
the liver, heart, kidney and gut [6,12,13]. This review presents a brief overview of the evidence
supporting the concept that a decrease in the bioavailability of NO coupled to increased
production of superoxide initiate a pathophysiological cascade that ultimately leads to post-
ischemic liver injury (Figure 1). The early innate immune responses occur in the absence of
an inflammatory infiltrate but will ultimately promote a net oxidative stress within the Kupffer
cells (KCs), sinusoidal endothelial cells (SECs) and hepatocytes thereby activating certain
oxidant-sensitive transcription factors and enhancing the expression of injurious pro-
inflammatory cytokines. The evidence implicating endogenous NO derived from endothelial
cell nitric oxide synthase (eNOS) as well as exogenous NO generated from the metabolism of
nitrite as important regulatory pathways molecule that limit I/R-induced liver injury are also
discussed in this review.
Post-Ischemic Liver Injury: Divergent Roles of Superoxide and Nitric Oxide
in the Acute Phase
The early phase of hepatocellular damage caused by I/R occurs within 1–6 hours following
reperfusion and appears to be associated with KC and possibly lymphocyte activation [1,3,5,
14]. This PMN-independent injury is thought to be initiated by an alteration in the redox state
of the liver producing a more oxidative environment within the cells of the tissue. The
mechanisms by which reperfusion of ischemic tissue induces this type of redox alteration is
not known with certainty but has been the subject of active investigation for more than 10
years. One of the earliest events associated with I/R is dysfunction of the SECs which is
characterized by a significant decrease in the steady state production of endothelial cell nitric
oxide synthase (eNOS)-derived NO [6,8–10]. The decrease in NO production occurs within 5
min of reperfusion and is most probably due to decreased synthesis of NO, enhanced
inactivation of NO by the overproduction of superoxide or both. Indeed, within minutes of
reperfusion, there is enhanced production of ROS such as superoxide (O2−), hydrogen peroxide
(H2O2) and/or hydroxyl radical (OH•) [1,3,15]. Cellular sources for these ROS that have been
implicated are hepatocyte-derived xanthine oxidase and/or mitochondria as well as KC- and/
or SEC-associated NADPH oxidase [1,3,15,16]. Although a great deal interest in hepatocyte-
associated xanthine oxidase was generated early on in investigations of liver I/R, more recent
work suggest that mitochondrial metabolism or KC-associated NADPH oxidase are probably
more important sources of ROS in the post-ischemic liver [15,17]. A recent study using an
isolated perfused liver preparation suggests that in the absence of Kupffer cells, hepatocytes
exhibit substantial oxidative stress suggesting the presence of additional ROS generators in
these cells as well [18]. Because certain oxygen-derived free radicals such as O2− will interact
with and decompose NO, I/R-induced over-production of this free radical and H2O2 (coupled
to decreased steady state levels of NO) will increase in redox potential of the liver from one
of a reduced redox state to a more oxidized redox environment [8,9,19,20]. In fact numerous
different studies, using pharmacologic interventions or genetic approaches have demonstrated
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significant protective effects of certain nonenzymatic or enzymatic antioxidants when
administered prior to inducing liver ischemia [3,5,15,21]. Although these studies have
identified a role for ROS in the pathophysiology of I/R-induced heptocellular injury, the
cellular source(s) for these ROS-mediated events as well as the mechanisms by which these
reactive species directly mediate hepatocyte damage have not been clearly delineated.
Superoxide and Post-Ischemic Liver Injury
Early studies into the role of ROS in the pathophysiology of liver I/R demonstrated significant
protective effects of a variety of non-specific free radical scavengers. However, with the advent
of new gene transfection technologies, more recent studies have shown that adenoviral
transfection of the liver with manganese superoxide dismutase (Mn-SOD) significantly
reduced post-ischemic liver injury implicating O2− as an important mediator of I/R injury [3].
While the use of adenoviral transfection of various SOD enzymes provides excellent
mechanistic information, the clinical and therapeutic usefulness of this approach is limited by
the known pro-inflammatory properties that these adenoviral vectors possess in the liver [22].
Exogenous administration of antioxidant enzymes such as SOD may provide a reasonable
therapeutic approach, these proteins (Cu/ZnSOD or MnSOD) have extremely short half-lives
(<7 minutes) in vivo making their use much less effective [23]. Chemical modifications of
these proteins such as the covalent ligation of polyethylene glycol have extended the life span
of these enzymes in the circulation [24–26]. Utilizing glycosylated forms of SOD thought to
be taken up by hepatocytes and/or Kupffer cells, Fujita and colleagues as well as Yabe and
associates were indeed able to significantly attenuate post-ischemic liver injury in the mouse
[24–26]. SOD conjugated to either galactose or mannose resulted in a 50% reduction in serum
ALT levels following 30 minutes of ischemia and 1 hour of reperfusion [24–26]. Further, these
studies identified the mannosylated form of SOD to be taken up by non-parenchymal cells (i.e.
endothelial cells, Kupffer cells, stellate cells, pit cells) resulting in substantial hepatocellular
protection. These data suggest that Kupffer cell or SEC-generated superoxide may directly or
indirectly mediate liver I/R injury.
Recent work by Gao and colleagues have demonstrated that SOD may be genetically
engineered to possess much longer half lives in vivo [23,27]. They have developed a fusion
protein composed of the human polycationic extracellular SOD (SOD3) and the mitochondrial
isoform MnSOD (SOD2). This fusion protein (SOD2/3) is capable of binding to the heparan
sulfate moieties on the microvascular endothelium as well as the interstitial matrix and has
been shown to have a greatly extended half-life (>30 hours) [15,18,23,27]. In contrast to the
other modified forms of SOD described above, SOD2/3 remains on the extracellular surface
of endothelial cells and hepatocytes allowing one to study the effects of extracellular O2−. We
have shown that pretreatment of mice with this SOD2/3 significantly attenuates the post-
ischemic liver injury incurred following 45 or 90 minutes of ischemia and 6 hours of reperfusion
(Figure 2) [15]. The protection observed with this enzyme also correlated well with significant
reductions in serum TNF-α, a known mediator of liver cell injury during I/R.
Taken together, these data clearly demonstrate that O2− mediates directly or indirectly much
of the I/R-induced tissue injury. A new class of non-enzymatic, low molecular weight,
membrane permeable, manganese-containing SOD mimetics have been created to circumvent
some of the problems associated with native or modified enzyme administration. As discussed
earlier, administration of native antioxidant enzymes is not therapeutically effective due to
their extremely short half-life. Furthermore, administration of large amounts of protein, native
or modified, in humans has been associated with immunological complications resulting in
their withdrawal from patient use. Manganese-containing protoporphyrin compounds are
devoid of these classical side effects. In experimental models of intestinal I/R, these compounds
have proven extremely effective. Salvemini et al were able to significantly attenuate post-
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ischemic neutrophil infiltration in the rat small intestine following 45 minutes of superior
mesenteric artery occlusion [15,28]. Further, these mimics have been associated with the
reduction of TNF-α expression following splanchnic I/R injury. The use of these compounds
in hepatic ischemia has also been examined. Treatment of mice with AEOL 10150 (Aeolus
Pharmaceuticals), significantly reduced the post-ischemic liver injury [15]. These data, coupled
to those obtained with the SOD2/3, suggest that both intracellular and extracellular O2− are
important in the pathogenesis of liver I/R injury.
A number of different cellular sources of O2− have proposed to account for post-ischemic tissue
injury. The most likely candidate is KC-associated NADPH oxidase although SEC NADPH
oxidase may also play a role as well. KC-NADPH oxidase is multi-component O2−-producing
protein complex that has been well-characterized in different phagocytic leukocytes and KCs.
Recent data suggest that a similar O2− generating complex is found in endothelial cells and
may be important for regulating vascular tone and blood flow [29]. In order to assess the
importance of NADPH oxidase in a mouse model liver I/R, mice deficient in the gp91phox
subunit of NADPH oxidase (gp91−/−) and lack the ability to produce O2- have been subjected
to liver I/R. We found that gp91phox deficiency attenuated the post-ischemic liver injury during
the acute phase [15]. Because the acute phase occurs in the absence of PMN infiltration, the
most likely cellular sources of NADPH oxidase are the KC and possibly the sinusoidal and/or
microvascular endothelial cells [16,30,31]. Indeed, inactivation of KC function by pretreatment
of mice with gadolinium chloride 24 hours prior to the induction of ischemia dramatically
reduce I/R-induced liver injury [15]. Exactly how NADPH oxidase-derived O2− directly or
indirectly promotes liver injury is not known with certainty. It may be that generation of O2−
early on during reperfusion may damage mitochondrial membrane lipids and proteins leading
either directly or indirectly to the loss of inner membrane potential and ATP generating capacity
[32]. In addition, O2− is known to inhibit certain enzymes within the mitochondria including
aconitase which may lead to substantial reductions in ATP formation and ultimately cell death
[33]. In addition to its direct effects, O2- may mediate hepatocellular damage indirectly via the
up-regulation of certain injurious cytokines such as TNF-α [34,35]. This is supported by our
observations that the protective effect of SOD2/3 and gp91 deficiency was associated with
reductions in serum TNF-α as well [15,36]. The molecular and signaling pathways that are
responsible for oxidant-induced cytokine production are discussed below.
Ischemia and Reperfusion Activates Transcription of Pro-Inflammatory Mediators
Over the years, enhanced production of ROS has been thought to injure cells and tissue via
their ability to oxidize and/or degrade critical cellular constituents. However, more recent
studies suggest that oxidant-induced tissue injury in the post-ischemic liver is not largely
dependent upon ROS-mediated oxidative degradation of lipids or other biomolecules [37]. It
is now thought that the pathophysiological effects of ROS may relate more to their ability to
induce oxidative stress within cells thereby up-regulating (or down-regulating) the expression
of certain redox-sensitive genes known to be important in cell proliferation, apoptosis and the
inflammatory response. In fact, several lines of evidence suggest that I/R-induced ROS
production may mediate hepatocellular injury and inflammation by activating redox-sensitive
transcription factors such as NF-kB and activating protein-1 (AP-1) [1,3,34,38–40]. Several
different studies demonstrate that liver I/R promotes nuclear translocation of NF-kB (and AP-1)
prior to the onset of major liver damage suggesting one or both of these transcription factors
may play critical roles in the pathogenesis of post-ischemic liver injury [1,3,34,39]. Although
AP-1, as well as other transcription factors may be involved in different aspects of gene
regulation in liver I/R, NF-kB is a critical regulatory element in initiating immune and
inflammatory responses making this transcription factor a prime candidate for regulating the
pathophysiology observed in liver I/R-induced injury. The mechanisms by which ROS-induced
activation of NF-kB promotes post-ischemic liver injury has been the subject of active
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investigations over the past few years. NF-kB is a ubiquitous transcription factor and
pleiotropic regulator of numerous inflammatory and immune response. Once activated, NF-
kB translocates to the nucleus of the cell where it binds to its consensus sequence on the
promoter-enhancer region of different genes thereby activating the transcription of genes
known to be important in the immune and inflammatory responses. For example, NF-kB
appears to regulate the transcription of several different cytokines (TNF-α, IL-1β, IL-2, IL-6,
IL-8, IL-12,), certain endothelial cell adhesion molecules (ECAMs) such as ICAM-1,
VCAM-1, E-selectin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) as well
as NOS 2 (iNOS) and COX 2 [1,3,34,39].
As previously mentioned, a number of different oxidants, bacterial and viral products,
cytokines and lipid mediators activate NF-kB. It is unlikely that each of these stimuli activates
cytoplasmic NF-kB-IkB via completely different pathways. Indeed, there is a growing body
of experimental data to suggest that many, if not all, of these stimuli activate multiple signaling
pathways, which converge to enhance reactive oxygen signaling within the cell. The identity
of the specific intracellular source(s) for this ROS signaling has (have) not been identified
however prostaglandin synthase, xanthine oxidase, mitochondria, NADPH oxidase and
cytochrome P-450 are likely candidates. NF-kB activation has also been shown to be inhibited
by a wide variety of structurally diverse enzymatic or non-enzymatic antioxidants or free
radical scavengers such as SOD, catalase, GSH peroxidase, N-acetylcysteine, vitamin E
derivatives, α-lipoic acid and certain dithiocarbamates. The mechanisms by which small
amounts of ROS activate NF-kB have not been defined. Intracellular oxidative stress is thought
to activate, directly or indirectly, one or more of the IKKs. Recent work by Karin and coworkers
suggest that ROS-mediated activation of NF-kB may be cell specific and may not occur in all
tissue [41]. The mechanisms by which NFkB-dependent generation of pro-inflammatory
cytokines mediate hepatocellular injury is not entirely clear. Investigations have suggested that
much of the post-ischemic liver injury may be a result of massive liver apoptosis induced by
TNF-α [42]. However, Jaeschke and coworkers found that when strict histopathological criteria
were used to score the livers, virtually all liver injury occurred by “osmotic necrosis” and very
little injury occurred by way of apoptosis [42]. However, it should be noted that the vast
majority of dead and dying cells in the post-ischemic liver are hepatocytes. It is conceivable
that SECs or KCs undergo significant apoptosis, which may not be apparent in whole liver
preparations.
Another emerging aspect of liver biology that is receiving substantial attention is the concept
that in addition to promoting tissue injury and inflammation, NF-kB activation may protect
cells and tissues from a variety of different insults by virtue of its ability enhance the
transcription of protective genes. Recent studies by Brenner and coworkers have confirmed
that overexpression of liver IkB-α in mice inhibited NF-kB activation resulting in massive
hepatocyte injury and apoptosis following partial hepatectomy in these animals [43]. The
mechanisms by which NF-kB activation protects the liver are only now becoming understood.
It is known for example that NF-kB activation induces several “anti-apoptotic” genes including
MnSOD, a zinc finger protein termed A20, cellular inhibitors of apoptosis-2 (c-IAP-2), and
Bcl-2 family members such as A1. Most of these genes (i.e. MnSOD, A20 and A1) are also
known to inhibit NF-kB activation and thus may control the expression of certain pro-
inflammatory genes. It may be that the balance between injurious vs protective genes
upregulated during I/R as well as the cellular location of NFkB activation dictates whether
NFkB activation will promote injury or protection.
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Hepatocellular Protection by Nitric Oxide or Nitrite in Post-Ischemic Liver
Injury
It is becoming increasingly appreciated that I/R results in rapid endothelial dysfunction in a
number of different tissues which is characterized by the marked decrease in steady state
production of endothelial cell-derived NO [6,8,10,20]. The decrease in NO bioavailability
occurs within the first few minutes following reperfusion and appears to be due to decreased
synthesis of NO, enhanced inactivation of NO by the overproduction of O2− or both. Because
NO is known to interact with and rapidly decompose certain ROS such as O2−, OH., and ferryl
hemoproteins, decreased steady state production of NO would in all likelihood increase the
redox potential of the hepatocyte, KC and/or SEC in favor of a more oxidative environment
[9,20,21]. Indeed, we have demonstrated that many of the pathophysiological charateristics
induced by I/R (i.e. oxidative stress, leukocyte adhesion, enhanced vascular permeability) may
be reproduced in normal tissue by administration of certain NOS inhibitors [8,10,20,44]. Taken
together, these data suggest that eNOS-derived NO may act as an endogenous anti-
inflammatory mediator in the microcirculation.
The use of certain NOS inhibitors to evaluate the role of NO in vivo has proven problematic.
It is known for example that L-NAME and L-NMMA are nonspecific inhibitors of both eNOS
and iNOS as well as potent vasoconstrictors in vivo [45]. Thus, the non-selective nature of
these NOS inhibitors coupled to the fact that their exacerbatory effects may be due to their
vasoconstrictor effects in a model of hypoperfusion makes their usefulness less than ideal to
probe the role for NO in liver I/R. The potentially protective role of endogenous NO in liver
I/R injury is supported by recently published studies demonstrating enhanced hepatocellular
injury in post-ischemic animals rendered deficient in eNOS (Figure 3) [11,46–48]. In addition,
investigators have demonstrated that NO donors or overexpression of liver eNOS protects mice
from liver I/R-induced injury [49–51]. Although eNOS has been shown by several groups of
investigators to play a critical protective role in liver I/R injury, the role of iNOS is less clear.
Studies from our laboratory suggest that I/R-induced liver injury is enhanced in iNOS-deficient
mice however interpretation of these data is complicated by the fact that we could not
demonstrate upregulation of iNOS message in post-ischemic livers of wild type mice
suggesting that the source of iNOS is not in the liver but in other tissue (ie intestine) or that a
small population of cells such as KCs or SECs upregulate iNOS which we are unable to detect
in whole liver preparations [52].
The mechanisms by which NO protects the liver against the injurious effects of I/R have not
been clearly defined but several possibilities have been proposed. For example NO is known
to inhibit NFkB activation. DeCaterina and coworkers provide evidence that NO enhances the
denovo synthesis and/or stabilization of the natural inhibitor IkB-α [7]. In addition, NO-
mediated S-nitrosation of a specific cysteine on the p50 and/or p65 subunits of NF-kB results
in inhibition of binding of this heterodimer to it consensus sequences upstream of the different
pro-inflammatory genes [53–55]. Furthermore, NO is known to interact with and decompose
O2− or other reactive radicals or oxidants thereby limiting the formation of O2− derived
H2O2 and preventing the downstream oxidant-induced pathways for NFkB activation [19].
Another possible mechanism may be that NO-dependent activation of soluble guanylyl cyclase
(sGC) with the subsequent production of the vasorelaxant cGMP may protect against
reperfusion injury by enhancing blood flow thereby limiting the degree of ischemia to the liver.
It has been proposed that NO-mediated activation of protein kinase G via the sGC/cGMP
pathway opens mitochondrial KATP channels which reduces calcium accumulation within the
mitochondria and prevents the loss of cytochromc c from the mitochondrial intermembranal
space (reviewed in [12])(Figure 4). Alternatively or in addition to, NO may reversibly inhibit
mitochondrial respiration via interaction with complex I and/or cytochrome c oxidase. This
would inhibit apoptosis, maintain small but significant amounts of O2 during ischemia and
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allow for a more controlled resumption of respiration following reperfusion [12] (Figure 4).
Similar observations have been made with NO-dependent S-nitrosation of caspase-3 resulting
in inactivation of this enzyme and inhibition of apoposis [12]. This would minimize free
radical-mediated damage to the mitochondrial membrane and preserve cellular function. NO
may attenuate the later stages of post-ischemic tissue damage by inhibiting platelet/leukocyte-
endothelial cell interactions [8,10,11].
Like any important signaling molecule, the generation and lifetime of NO is very short-lived
in vivo. Indeed, NO may be inactivated rapidly by at least 3 different pathways. The first
pathways involves the autoxidation of NO to nitrite (NO2−):
Although this pathway has been proposed to be a likely mechanism for NO decomposition in
vivo, it is a 3rd order reaction with respect to NO interacting with O2 making this pathway too
slow and unlikely to occur under physiological conditions. A more physiologically-relevant
set of pathways for the inactivation of NO may be mediated by metal-catalyzed oxidation
reactions. The copper-containing protein ceruloplasmin (P-Cu+2) has been shown to rapidly
oxidize NO to NO2− under physiological conditions[56]:
In addition to ceruloplasmin, ferrous dioxygenated hemoglobin (Hb-Fe+2O2; oxyhemoglobin)
rapidly rapidly decomposes NO to yield nitrate (NO3−):
These data suggest that circulating levels of nitrite and nitrate may be used to assess NOS
activity in vivo. Indeed, eNOS deficient mice have plasma levels of nitrite that are only 30%
of those found in wild type mice suggesting that eNOS-derived NO represents a major source
of nitrite in the circulation [56]. In reality, nitrate is present in significantly greater
concentrations that nitrite in the blood (25–35 uM vs 0.15–0.35 uM, respectively)[56]. In
addition to NO-derived nitrite and nitrate, large amounts of nitrogen oxides are ingested in the
diet from consumption of leafy vegetables (nitrate) and cured meats (nitrite) and contribute
significantly to overall plasma levels of nitrate and nitrite. It has been estimated that one plate
of leafy vegetables (lettuce, spinach) contains three times more nitrate (and nitrite) than can
be produced by all 3 NOS isoforms in one day [56]. Historically, it has been assumed that
blood and tissue nitrate and nitrite simply reflected inert endproducts of NO metabolism and
food contaminants. However, it is now recognized that these oxidized metabolites of nitrogen
can be metabolized in vivo to regenerate NO. This happens in two basic steps. The first step
involves the reduction of nitrate to nitrite by the action nitrate reductase found in certain enteric
and oral bacteria[56]:
Once formed, NO2− can be reduced further to yield NO via several different pathways. The
first and best characterized is by the acid-catalzed disproportionation of nitrous acid (HNO2)
via the intermediate formation of dinitrogen trioxide (N2O3):
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This reaction is greatly enhanced by the presence of asorbic acid or different polyphenolic
compounds [56]. In addition, nitrite can be reduced to NO by xanthine oxidoreductase (XO)
or by ferrous deoxygenated hemoglobin or myoglobin (P-Fe+2):
Although much of the NO produced would escape the heme moiety making it available for
further interactions, a portion of the NO would be trapped by the heme to form nitrosyl-
hemoglobin (or myoglobin). The physiological significance of nitrosyl-heme formation is not
clear at the present time. Taken together, these data demonstrate that endogeous or dietary
nitrate and nitrite can be metabolized and recycled in vivo to generate biologically active NO.
Because the rate of NO generation from nitrite is linearly dependent on reductions in tissue
pO2 and pH, nitrite may be metabolized to NO in ischemic tissue (via deoxyHb or Mb) and
exert NO-dependent protective effects site-specifically. Indeed, the tissue-specific reduction
of nitrite to generate cytoprotective NO has important clinical significance in that treatment of
different ischemic disorders with nitrite would reduce the untoward cardiovascular effects of
systemic delivery of inhaled NO or intravenous administration of S-nitrosothiols. Indeed, a
growing number of studies demonstrate that nitrite is cytoprotective in different models of
tissue I/R including the liver, heart, kidney and brain [12]. The clinical usefulness of nitrite is
currently being investigated as a potential therapeutic agent to treat ischemic disorders.
Concluding Remarks
There is now overwhelming evidence supporting a role for NO generated by eNOS or from
nitrite as an important regulatory molecule that acts to limit post-ischemic tissue injury. The
mechanisms by which this free radical protects the reperfused liver remain to be defined and
is the subject of active investigation. Therapeutic uses of NO or nitrite are currently underway
in several different laboratories to treat a variety of ischemic disorders.
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Figure 1. Proposed pathophysiological mechanisms thought to be important in liver ischemia and
reperfusion injury
Ischemia and reperfusion of the liver induces a decrease in the bioavailability of NO
concomitant with enhanced production of reactive oxygen species (ROS). This redox
imbalance results in an alteration of the redox potential of the liver thereby producing a more
oxidative environment. Enhanced “oxidative stress” within the Kupffer cells, sinusoidal
endothelial cells and hepatocytes would promote the NFkB-dependent expression of certain
pro-inflammatory cytokines that may injure the tissue.
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Figure 2. Effect of SOD2/3 on ischemia and reperfusion liver injury
Mice were treated with the fusion protein SOD2/3 (1,000 U/kg, iv) or vehicle 15 minutes prior
to being subjected to 90 minutes of ischemia and 6 hours of reperfusion. * p<0.05 vs. vehicle-
treated mice controls. n ≥ 6 animals per group. Data derived from reference 15.
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Figure 3. Effect of eNOS deficiency on ischemia and reperfusion liver injury
eNOS deficient (eNOS−/−) or wild type mice were subjected to 45 minutes of ischemia and 6
hours of reperfusion. * p<0.05 vs. sham-operated mice; #p<0.05 vs. time matched wild type
mouse. n ≥ 6 animals per group. Data derived from reference 15.
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Figure 4. Proposed cytoprotective mechanisms for nitric oxide
Nitric oxide (NO) derived from endothelial nitric oxide synthase or from the enzymatic
(deoxyhemobin, dexoymyoglobin, cytochromes, xanthine oxidorectase) or nonenyzmatic
(acid-dependent disproportionation) reduction of nitrite (NO2−) may protect tissue subjected
to ischemia and reperfusion by: a) Inactivation of caspase-3 via the NO-dependent S-nitrosation
of the protein; b) cGMP/protein kinase G (cGMP/PKG)-mediated opening of mitochondrial
ATP-dependent potassium channels (KATP) which reduces the loss of cytochrome C, decreases
calcium accumulation within the mitochondria, prevent the opening of the mitochondrial
permeablility transition (MPT) pore and decrease apoptosis; c) inhibition of mitochondrial
electron transport via the direct or indirect (S-nitrosation) inhibition of Complex I (and possible
Complex IV) resulting in decreased reactive oxygen specie (ROS) generation, reduced
cytochrome C release and decreased apoptosis.
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